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geﬁ tinib versus all doublet chemotherapies (geﬁ tinib vs. pemetrexed/cisplatin OR 3.05, 
95% CrI: 1.58–5.51). CONCLUSIONS: This adjusted indirect comparison suggests 
that geﬁ tinib may have important ORR advantages over other ﬁ rst-line treatments in 
EGFR-TK M+ patients.
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OBJECTIVES: Standard ﬁ rst-line treatment for patients with mHRPC is Docetaxel(D)-
based chemotherapy. Published results from randomized clinical trials of second-line 
treatments after D failed to provide deﬁ nitive conclusions about clinical efﬁ cacy largely 
due to paucity of data. This study sought to identify nonrandomized trials of second-
line chemotherapy in mHRPC patients pretreated with D and present related survival 
and clinical beneﬁ ts. METHODS: Pubmed and Embase were used to perform a sys-
tematic literature review (SLR) (2000–2010). Both comparative and noncomparative 
nonrandomized evidence were extracted from prospective and retrospective studies. 
Targeted population was patients with mHRPC failing previous D-based regimens. 
End points included overall-survival (OS), progression-free-survival (PFS), and PSA-
response rate. RESULTS: Among the 825 records screened, 30 studies met the inclu-
sion criteria, two of which were comparative. Of these, 10 addressed rechallenge with 
D and seven addressed mitoxantrone (MTX); the remaining 18 studies considered 
various other regimens. Treatment was with either single-agent or combination regi-
mens. Ninety-three percent of studies included <50 patients. PFS and PSA response 
deﬁ nitions varied between trials. For studies evaluating rechallenge with D, the median 
OS and PFS varied from 41 to 76 weeks and from 15 to 39 weeks respectively. For 
MTX, the median OS and PFS varied from 39 to 48 weeks and 13 to 16 weeks, 
respectively. For other chemotherapy regimens, the median OS and PFS varied from 
51 to 104 weeks and 9 to 17 weeks, respectively. PSA response rates varied from 24% 
to 70% to D rechallenge, from 4% to 33% to MTX-based regimens and from 0% to 
60% to other regimens. CONCLUSIONS: The SLR showed a lack of available non-
randomized evidence, and among the selected studies, evidence was not strong enough 
due to small sample sizes, noncomparative nature and variable PFS and PSA response 
deﬁ nitions. This literature review demonstrates that it is difﬁ cult to infer the clinical 
efﬁ cacy of mHRPC 2nd line chemotherapy.
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OBJECTIVES: Patients with breast cancer (BC) and bone metastases are at risk for 
skeletal-related events (SREs) that are associated with signiﬁ cant morbidity, mortality, 
and reduced quality of life. The intravenous bisphosphonates (IVBPs) zoledronic acid 
(ZOL) and pamidronate (PAM) are approved for treating patients with bone metas-
tases from BC. We compared incidence of SREs and mortality in women with BC who 
received ZOL or PAM, and assessed the long-term beneﬁ t of ZOL in a real-world 
setting. METHODS: A claims-based analysis of commercial and Medicare Advantage 
data from >45 US managed care plans was used to evaluate SRE rates and mortality 
in patients treated with ZOL or PAM. Inclusion criteria were age >18 years, BC with 
bone metastasis diagnosis between 01/01/01 and 12/31/06, continuous enrollment in 
the health plan, no evidence of bone metastasis or IVBP for 6 months before an index 
date of ﬁ rst receipt of ZOL or PAM. Patients were followed until disenrollment 
(including mortality) or study completion (12/31/07). Persistency was deﬁ ned as the 
absence of a >45-day gap between treatments. SREs were deﬁ ned as evidence of 
pathologic fracture, spinal cord compression, and radiotherapy or surgery to bone. 
RESULTS: Among 8757 patients (mean age, 58.1 ± 12.4 years) approximately 30% 
received ZOL, 15% received PAM, and 55% received no IVBP. Longer persistency 
with ZOL was associated with lower risk of fracture and of all SREs versus shorter 
persistency (trend test, P = 0.0026 and P = 0.0216, respectively). ZOL-treated patients 
had a moderately lower SRE incidence (36.2 vs. 40.0 per 100 person-years; P = 
0.0707) and signiﬁ cantly fewer deaths (6.2 vs. 8.9 per 100 person-years; P = 0.0130) 
versus PAM-treated patients. CONCLUSIONS: In a real-world assessment of women 
with bone metastases from BC, ZOL reduced SRE incidence and signiﬁ cantly 
improved survival versus PAM. Longer ZOL persistency was associated with lower 
SRE risk, reinforcing the importance of regular monthly ZOL dosing.
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OBJECTIVES: To assess the clinical consequences of primary prophylaxis (PP) with 
pegﬁ lgrastim versus 6- or 11-day ﬁ lgrastim (F6, F11) in the prevention of febrile 
neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients receiving CHOP-14 
chemotherapy and in breast cancer (BC) patients receiving TAC chemotherapy in 
Germany. METHODS: A lifetime Markov model was developed, consisting of two 
phases: 1) on-chemotherapy phase (OCP), where model cycle length equals chemo-
therapy cycle length (CHOP-14:14 days, TAC: 21 days), and 2) post-chemotherapy 
phase (PCP) with annual model cycles. PP is deﬁ ned as prophylaxis initiated with the 
ﬁ rst chemotherapy cycle. Cycle 1 FN risk with no prophylaxis (NP) was estimated to 
be 21% for NHL CHOP-14 and 14% for BC TAC. All cycle relative risk of FN using 
PP with pegﬁ lgrastim versus no PP, F6, and F11 was 0.25, 0.87, and 0.61. FN case 
fatality was estimated (NHL: 8.9%; BC: 3.6%). In PCP, all-cause mortality was 
estimated from German life-tables; NHL and BC mortality from US data; patients 
experiencing FN were assumed to have higher mortality due to reduced chemotherapy 
dose intensity. All inputs were estimated from clinical trials and published literature. 
The model estimates life-years, number of FNs, and number needed to treat (NNT) 
to prevent an FN. RESULTS: NNT to prevent an FN were 1.3, 6.2, 2.2 in NHL; 2.3, 
11.1, 4.0 in BC for Pegﬁ lgrastim, F6, and F11 compare to NP. Overall, FN episodes 
per patient were 0.15, 0.76, and 0.47 in NHL; 0.09, 0.43, and 0.27 in BC. Per-patient 
life-months gained using PP with Pegﬁ lgrastim were 3.4 and 1.8 versus F6 and F11, 
respectively in NHL, and 2.2 and 1.2 in BC. CONCLUSIONS: Primary prophylaxis 
with pegﬁ lgrastim results in a lower NNT, fewer FN events, and more life-years than 
with 6-day ﬁ lgrastim or 11-day ﬁ lgrastim in both NHL and BC.
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OBJECTIVES: To undertake a systematic review of lapatinib plus letrozole (LAP + 
LET) with other ﬁ rst-line treatments for HR+ HER2+ advanced or MBC in postmeno-
pausal women who have not received prior therapy for advanced or metastatic disease. 
METHODS: Seven databases were searched through January 2009 for randomized 
controlled trials. Relevant interventions were lapatinib (alone/in combination), aro-
matase inhibitors (letrozole (LET), anastrozole (ANA), exemestane (EXE)), tamoxifen 
(TAM), and trastuzumab (TRAS) (alone/in combination). Outcomes included overall 
survival (OS), progression-free survival (PFS), time to progression (TTP), and objective 
response rate (ORR). From the available evidence, it was possible to directly compare 
LAP + LET with LET. Using a network meta-analysis, LAP + LET could be indirectly 
compared with the four other interventions. RESULTS: Eighteen studies (62 papers) 
met the inclusion criteria. LAP + LET was signiﬁ cantly superior to LET based on a 
direct head-to-head study in terms of PFS/TTP and ORR. In the indirect comparison 
with LAP + LET, TAM (hazard ratio [HR] = 0.45 [95% CI: 0.32, 0.65]), EXE (HR 
= 0.52 [0.34, 0.79]), and ANA (HR = 0.53 [0.36, 0.80]) scored signiﬁ cantly worse in 
terms of PFS/TTP and ORR (TAM: odds ratio [OR] = 0.25 [0.12, 0.53], ANA: OR 
= 0.27 [0.12, 0.58], EXE: OR = 0.47 [0.20, 1.09]). LAP + LET also seemed better, 
although not signiﬁ cantly, in terms of OS versus TAM: HR = 0.74 (0.49, 1.12), EXE: 
HR = 0.65 (0.39, 1.11), and ANA: HR = 0.71 (0.45, 1.14). LAP + LET when indirectly 
compared with TRAS + ANA, seemed to be better in terms of OS (HR = 0.85 [0.47, 
1.54]), PFS/TTP (HR = 0.89 [0.54, 1.47]) and ORR (OR = 0.92 [0.24, 3.48]), 
although, none of these results were signiﬁ cant. CONCLUSIONS: Using indirect 
methods, LAP + LET appeared to be the best treatment in this HR+ HER2+ patient 
population. However, the results are based on a network analysis for which the basic 
assumptions of homogeneity, similarity, and consistency were not fulﬁ lled. Therefore, 
despite the fact that these are the best available data, the results need to be interpreted 
with caution.
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OBJECTIVES: To compare the efﬁ cacy in progression-free survival (PFS) of bevaci-
zumab plus cisplatin and gemcitabine (BCG) and bevacizumab plus carboplatin and 
paclitaxel (BCP), relative to doublet-chemotherapy combinations for the treatment of 
